{"id":"NCT00484198","sponsor":"Daiichi Sankyo","briefTitle":"Study of Rivoglitazone in Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04-23","primaryCompletion":"2009-02-12","completion":"2009-02-12","firstPosted":"2007-06-08","resultsPosted":"2021-07-27","lastUpdate":"2021-07-27"},"enrollment":1912,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Pioglitazone","otherNames":["Actos"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rivoglitazone","otherNames":[]},{"type":"DRUG","name":"Rivoglitazone","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"ACTIVE_COMPARATOR"}],"summary":"This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.","primaryOutcome":{"measure":"Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus","timeFrame":"Baseline up to week 26 post-dose","effectByArm":[{"arm":"Placebo","deltaMin":7.7,"sd":0.55},{"arm":"Rivoglitazone 1.0 mg","deltaMin":7.7,"sd":0.54},{"arm":"Rivoglitazone 1.5mg","deltaMin":7.7,"sd":0.57},{"arm":"Pioglitazone 45 mg","deltaMin":7.7,"sd":0.58}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":183,"countries":["United States","Argentina","Austria","Chile","Czechia","Germany","Hungary","India","Latvia","Mexico","Peru","Puerto Rico","Romania","Serbia","Slovakia","South Africa","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":137},"commonTop":["Edema peripheral","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Headache"]}}